HIF1A and pachyonychia congenita: Numerous studies have been carried out to establish the therapeutic benefit to down-regulate expression levels, stability and/or transcriptional activity of HIF-1α and/or HIF-2α by RNA interference or using pharmacological inhibitors of HIFs to eradicate PC cells [8, 54, 57–61, 202, 206, 218–222].